Targeting protein serine/threonine phosphatases for drug development

Molecular Pharmacology

Volumn 75, Issue 6, 2009, Pages 1249-1261

  McConnell, Jamie L ^a   Wadzinski, Brian E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALYCULIN A; CANTHARIDIN; CYCLOSPORIN A; FINGOLIMOD; FOSTRIECIN; HISTONE DEACETYLASE INHIBITOR; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL PRODUCT; NORCANTHARIDIN; OKADAIC ACID; PHOSLACTOMYCIN A; PHOSLACTOMYCIN B; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE; SALUBRINAL; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COMPLEX FORMATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LIVER CELL CARCINOMA; LIVER TOXICITY; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; DRUG DISCOVERY; ENZYME ACTIVATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPROTEIN COMPLEXES; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES;

EID: 66849115406     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053140     Document Type: Short Survey

References (154)

1. Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, Hemmings BA, Dilworth SM, Mischak H, Kolch W, and Baccarini M (2000) Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 275:22300-22304. (Pubitemid 30621814)
2. Adams DG, Coffee RL Jr, Zhang H, Pelech S, Strack S, and Wadzinski BE (2005) Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. J Biol Chem 280:42644-42654. (Pubitemid 43049223)
3. Aggen JB, Humphrey JM, Gauss CM, Huang HB, Nairn AC, and Chamberlin AR (1999) The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: rational modifications imparting PP1 selectivity. Bioorg Med Chem 7:543-564. (Pubitemid 29117214)
4. Arnold HK and Sears RC (2006) Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol 26:2832-2844.
5. Arroyo JD and Hahn WC (2005) Involvement of PP2A in viral and cellular transformation. Oncogene 24:7746-7755. (Pubitemid 41670676)
6. Baba Y, Hirukawa N, and Sodeoka M (2005) Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode. Bioorg Med Chem 13:5164-5170. (Pubitemid 41039976)
7. Baba Y, Hirukawa N, Tanohira N, and Sodeoka M (2003) Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin). J Am Chem Soc 125:9740-9749. (Pubitemid 36975936)
8. Barford D, Das AK, and Egloff MP (1998) The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu Rev Biophys Biomol Struct 27:133-164. (Pubitemid 28286012)
9. Barik S (2006) Immunophilins: for the love of proteins. Cell Mol Life Sci 63:2889-2900. (Pubitemid 46072296)
10. Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, and Blakely RD (2000) Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci 20:7571-7578.
11. Bauman AL and Scott JD (2002) Kinase- and phosphatase-anchoring proteins: harnessing the dynamic duo. Nat Cell Biol 4:E203-206. (Pubitemid 34905592)
12. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136.
13. Beeram M, Patnaik A, and Rowinsky EK (2005) Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23:6771-6790. (Pubitemid 46194105)
14. Belova GI, Demidov ON, Fornace AJ Jr, and Bulavin DV (2005) Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol Ther 4:1154-1158. (Pubitemid 41598573)
15. 1/S phase cell cycle arrest. J Biol Chem 277:27449-27467.
16. Bialojan C and Takai A (1988) Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 256:283-290.
17. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, et al. (2005) A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307:935-939. (Pubitemid 40229232)
18. Brautigan DL, Brown M, Grindrod S, Chinigo G, Kruszewski A, Lukasik SM, Bushweller JH, Horal M, Keller S, Tamura S, et al. (2005) Allosteric activation of protein phosphatase 2C by D-chiro-inositol-galactosamine, a putative mediator mimetic of insulin action. Biochemistry 44:11067-11073. (Pubitemid 41209042)
19. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457. (Pubitemid 34952287)
20. Brush MH, Guardiola A, Connor JH, Yao TP, and Shenolikar S (2004) Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279:7685-7691. (Pubitemid 38294650)
21. Bryant JC, Westphal RS, and Wadzinski BE (1999) Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem J 339:241-246. (Pubitemid 29209953)
22. Bryant KF, Macari ER, Malik N, Boyce M, Yuan J, and Coen DM (2008) ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells. Virology 379:197-204.
23. Buck SB, Hardouin C, Ichikawa S, Soenen DR, Gauss CM, Hwang I, Swingle MR, Bonness KM, Honkanen RE, and Boger DL (2003) Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. J Am Chem Soc 125:15694-15695. (Pubitemid 37553657)
24. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, and Fornace AJ Jr (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36:343-350. (Pubitemid 38437256)
25. Canettieri G, Morantte I, Guzmán E, Asahara H, Herzig S, Anderson SD, Yates JR 3rd, and Montminy M (2003) Attenuation of a phosphorylation- dependent activator by an HDAC-PP1 complex. Nat Struct Biol 10:175-181.
26. Carmody LC, Baucum AJ 2nd, Bass MA, and Colbran RJ (2008) Selective targeting of the gamma1 isoform of protein phosphatase 1 to F-actin in intact cells requires multiple domains in spinophilin and neurabin. FASEB J 22:1660-1671.
27. Carmody LC, Bauman PA, Bass MA, Mavila N, DePaoli-Roach AA, and Colbran RJ (2004) A protein phosphatase-1γ1 isoform selectivity determinant in dendritic spine-associated neurabin. J Biol Chem 279:21714-21723. (Pubitemid 38679357)
28. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA, and Kim JY (2008) Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86:245-256.
29. Ceulemans H and Bollen M (2004) Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev 84:1-39. (Pubitemid 38049874)
30. Chalfant CE, Kishikawa K, Mumby MC, Kamibayashi C, Bielawska A, and Hannun YA (1999) Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 274:20313-20317. (Pubitemid 129519507)
31. Chalfant CE, Szulc Z, Roddy P, Bielawska A, and Hannun YA (2004) The structural requirements for ceramide activation of serine-threonine protein phosphatases. J Lipid Res 45:496-506. (Pubitemid 38337996)
32. Chelu MG, Danila CI, Gilman CP, and Hamilton SL (2004) Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med 14:227-234. (Pubitemid 39297020)
33. Chen CS, Weng SC, Tseng PH, Lin HP, and Chen CS (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280:38879-38887. (Pubitemid 43853791)
34. Chen J, Martin BL, and Brautigan DL (1992) Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257:1261-1264.
35. Chen M and Beck WT (1993) Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53:5946-5953. (Pubitemid 24006165)
36. Chen MS, Silverstein AM, Pratt WB, and Chinkers M (1996) The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J Biol Chem 271:32315-32320. (Pubitemid 26422271)
37. Chen MX, McPartlin AE, Brown L, Chen YH, Barker HM, and Cohen PT (1994) A novel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. EMBO J 13:4278-4290. (Pubitemid 24295200)
38. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, and Hahn WC (2004) Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5:127-136. (Pubitemid 38283799)
39. Chiba K (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 108:308-319. (Pubitemid 41691870)
40. Cho US and Xu W (2007) Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445:53-57. (Pubitemid 46067298)
41. Chong H, Vikis HG, and Guan KL (2003) Mechanisms of regulating the Raf kinase family. Cell Signal 15:463-469. (Pubitemid 36292166)
42. Clipstone NA and Crabtree GR (1992) Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695-697.
43. Cohen P (2002a) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309-315. (Pubitemid 37361447)
44. Cohen PT (2002b) Protein phosphatase 1-targeted in many directions. J Cell Sci 115:241-256. (Pubitemid 34145174)
45. Connor JH, Kleeman T, Barik S, Honkanen RE, and Shenolikar S (1999) Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors. J Biol Chem 274:22366-22372. (Pubitemid 129529247)
46. Courtois G and Gilmore TD (2006) Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25:6831-6843. (Pubitemid 44657855)
47. Delhase M, Hayakawa M, Chen Y, and Karin M (1999) Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 284:309-313. (Pubitemid 129523447)
48. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, and Karin M (1997) A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388:548-554. (Pubitemid 27339997)
49. Dobrowsky RT, Kamibayashi C, Mumby MC, and Hannun YA (1993) Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 268:15523-15530. (Pubitemid 23222045)
50. Ducruet AP, Vogt A, Wipf P, and Lazo JS (2005) Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol 45:725-750. (Pubitemid 40261823)
51. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, and Barford D (1997) Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO J 16:1876-1887. (Pubitemid 27170949)
52. Fiedler B and Wollert KC (2005) Targeting calcineurin and associated pathways in cardiac hypertrophy and failure. Expert Opin Ther Targets 9:963-973. (Pubitemid 41488834)
53. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'Connor PM, and Appella E (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 94:6048-6053. (Pubitemid 27270633)
54. Fu DX, Kuo YL, Liu BY, Jeang KT, and Giam CZ (2003) Human T-lymphotropic virus type I tax activates I-κB kinase by inhibiting I-κB kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 278:1487-1493. (Pubitemid 36801375)
55. Gallego M and Virshup DM (2005) Protein serine/threonine phosphatases: life, death, and sleeping. Curr Opin Cell Biol 17:197-202. (Pubitemid 40380944)
56. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, and Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296. (Pubitemid 39061110)
57. Guergnon J, Dessauge F, Dominguez V, Viallet J, Bonnefoy S, Yuste VJ, Mercereau-Puijalon O, Cayla X, Rebollo A, Susin SA, et al. (2006) Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol 69:1115-1124.
58. Guo C, Mi J, Brautigan DL, and Larner JM (2007) ATM regulates ionizing radiation-induced disruption of HDAC1:PP1:Rb complexes. Cell Signal 19:504-510. (Pubitemid 46107801)
59. Hayden MS and Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344-362.
60. Heidecker G, Huleihel M, Cleveland JL, Kolch W, Beck TW, Lloyd P, Pawson T, and Rapp UR (1990) Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10:2503-2512. (Pubitemid 20177974)
61. Hill TA, Stewart SG, Ackland SP, Gilbert J, Sauer B, Sakoff JA, and McCluskey A (2007a) Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation. Bioorg Med Chem 15:6126-6134. (Pubitemid 47088962)
62. Hill TA, Stewart SG, Gordon CP, Ackland SP, Gilbert J, Sauer B, Sakoff JA, and McCluskey A (2008) Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition. Chem Med Chem 3:1878-1892.
63. Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland SP, Sakoff JA, and McCluskey A (2007b) Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg Med Chem Lett 17:3392-3397. (Pubitemid 46819022)
64. Honkanen RE (1993) Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 330:283-286. (Pubitemid 23276340)
65. Honkanen RE and Golden T (2002) Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem 9:2055-2075. (Pubitemid 35256504)
66. Huai Q, Kim HY, Liu Y, Zhao Y, Mondragon A, Liu JO, and Ke H (2002) Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A 99:12037-12042.
67. Jackson RC, Fry DW, Boritzki TJ, Roberts BJ, Hook KE, and Leopold WR (1985) The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv Enzyme Regul 23:193-215.
68. Janssens V and Goris J (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417-439. (Pubitemid 32158309)
69. Jia Z (1997) Protein phosphatases: structures and implications. Biochem Cell Biol 75:17-26. (Pubitemid 127733123)
70. Kamenski T, Heilmeier S, Meinhart A, and Cramer P (2004) Structure and mechanism of RNA polymerase II CTD phosphatases. Mol Cell 15:399-407. (Pubitemid 39092756)
71. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436. (Pubitemid 44050137)
72. Kawada M, Kawatsu M, Masuda T, Ohba S, Amemiya M, Kohama T, Ishizuka M, and Takeuchi T (2003) Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells. Int Immunopharmacol 3:179-188. (Pubitemid 36183377)
73. Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showalter RE, and Moomaw EW (1995) Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378:641-644. (Pubitemid 3005789)
74. Kray AE, Carter RS, Pennington KN, Gomez RJ, Sanders LE, Llanes JM, Khan WN, Ballard DW, and Wadzinski BE (2005) Positive regulation of IκB kinase signaling by protein serine/threonine phosphatase 2A. J Biol Chem 280:35974-35982. (Pubitemid 41633866)
75. Law B and Rossie S (1995) The dimeric and catalytic subunit forms of protein phosphatase 2A from rat brain are stimulated by C2-ceramide. J Biol Chem 270:12808-12813.
76. Lazar DF and Saltiel AR (2006) Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov 5:333-342.
77. Letourneux C, Rocher G, and Porteu F (2006) B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J 25:727-738. (Pubitemid 43292435)
78. Lewy DS, Gauss CM, Soenen DR, and Boger DL (2002) Fostriecin: chemistry and biology. Curr Med Chem 9:2005-2032. (Pubitemid 35256502)
79. Li HY, Liu H, Wang CH, Zhang JY, Man JH, Gao YF, Zhang PJ, Li WH, Zhao J, Pan X, et al. (2008) Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat Immunol 9:533-541.
80. Li S, Wang L, Berman MA, Zhang Y, and Dorf ME (2006) RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. Mol Cell 24:497-509. (Pubitemid 350284222)
81. Li YM and Casida JE (1992) Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci U S A 89:11867-11870. (Pubitemid 23004745)
82. Lin HY, Chen CS, Lin SP, Weng JR, and Chen CS (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397-413. (Pubitemid 43939200)
83. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, and Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815. (Pubitemid 121001714)
84. Liu Q and Hofmann PA (2004) Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes. Am J Physiol Heart Circ Physiol 286:H2204-H2212. (Pubitemid 38685234)
85. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, et al. (2008) FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111:275-284.
86. Lyon MA, Ducruet AP, Wipf P, and Lazo JS (2002) Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov 1:961-976. (Pubitemid 37361602)
87. Macian F (2005) NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5:472-484. (Pubitemid 40835035)
88. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349. (Pubitemid 34303689)
89. Marciniak SJ and Ron D (2006) Endoplasmic reticulum stress signaling in disease. Physiol Rev 86:1133-1149. (Pubitemid 44521649)
90. Martínez-Martínez S and Redondo JM (2004) Inhibitors of the calcineurin/NFAT pathway. Curr Med Chem 11:997-1007. (Pubitemid 38425927)
91. Matsuoka Y, Nagahara Y, Ikekita M, and Shinomiya T (2003) A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 138:1303-1312. (Pubitemid 36543128)
92. McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, and Baldwin ML (2000) Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 10:1687-1690. (Pubitemid 30495241)
93. Michael LF, Asahara H, Shulman AI, Kraus WL, and Montminy M (2000) The phosphorylation status of a cyclic AMP-responsive activator is modulated via a chromatin-dependent mechanism. Mol Cell Biol 20:1596-1603. (Pubitemid 30100179)
94. Morishita W, Connor JH, Xia H, Quinlan EM, Shenolikar S, and Malenka RC (2001) Regulation of synaptic strength by protein phosphatase 1. Neuron 32:1133-1148. (Pubitemid 34075402)
95. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, et al. (2009) Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 23:751-763.
96. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, et al. (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117:2408-2421. (Pubitemid 47494343)
97. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al. (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8:355-368. (Pubitemid 41579831)
98. Ory S, Zhou M, Conrads TP, Veenstra TD, and Morrison DK (2003) Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol 13:1356-1364. (Pubitemid 37029425)
99. Palaniappan N, Kim BS, Sekiyama Y, Osada H, and Reynolds KA (2003) Enhancement and selective production of phoslactomycin B, a protein phosphatase IIa inhibitor, through identification and engineering of the corresponding biosynthetic gene cluster. J Biol Chem 278:35552-35557. (Pubitemid 37102327)
100. Palkowitsch L, Leidner J, Ghosh S, and Marienfeld RB (2008) Phosphorylation of serine 68 in the IκB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-α-induced NFκB activity. J Biol Chem 283:76-86.
101. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, and Roberts TM (1990) Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 60:167-176. (Pubitemid 20033919)
102. Parameswara VK, Sule AJ, and Esser V (2005) Have we overlooked the importance of serine/threonine protein phosphatases in pancreatic beta-cells? Role played by protein phosphatase 2A in insulin secretion. JOP 6:303-315. (Pubitemid 41581750)
103. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, and Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466. (Pubitemid 39329586)
104. Prajapati S, Verma U, Yamamoto Y, Kwak YT, and Gaynor RB (2004) Protein phosphatase 2Cβassociation with the IκB kinase complex is involved in regulating NF-κB activity. J Biol Chem 279:1739-1746. (Pubitemid 38084441)
105. Price NE and Mumby MC (2000) Effects of regulatory subunits on the kinetics of protein phosphatase 2A. Biochemistry 39:11312-11318.
106. Ramsey AJ and Chinkers M (2002) Identification of potential physiological activators of protein phosphatase 5. Biochemistry 41:5625-5632. (Pubitemid 34429396)
107. Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, and Anderson H (1994) Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 54:6115-6121. (Pubitemid 24378641)
108. Roehrl MH, Kang S, Aramburu J, Wagner G, Rao A, and Hogan PG (2004) Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci U S A 101:7554-7559. (Pubitemid 38658067)
109. Rogers JP, Beuscher AE 4th, Flajolet M, McAvoy T, Nairn AC, Olson AJ, and Greengard P (2006) Discovery of protein phosphatase 2C inhibitors by virtual screening. J Med Chem 49:1658-1667.
110. Ruediger R, Fields K, and Walter G (1999) Binding specificity of protein phosphatase 2A core enzyme for regulatory B subunits and T antigens. J Virol 73:839-842. (Pubitemid 28565438)
111. Ruediger R, Pham HT, and Walter G (2001a) Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 20:1892-1899. (Pubitemid 32458699)
112. Ruediger R, Pham HT, and Walter G (2001b) Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 20:10-15. (Pubitemid 32142333)
113. Rusnak F and Mertz P (2000) Calcineurin: form and function. Physiol Rev 80:1483-1521.
114. Sakoff JA and McCluskey A (2004) Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Curr Pharm Des 10:1139-1159.
115. Schweighofer A, Hirt H, and Meskiene I (2004) Plant PP2C phosphatases: emerging functions in stress signaling. Trends Plant Sci 9:236-243. (Pubitemid 38617222)
116. Sieder S, Richter E, Becker K, Heins R, and Steinfelder HJ (1999) Doxorubicin-resistant LoVo adenocarcinoma cells display resistance to apoptosis induction by some but not all inhibitors of ser/thr phosphatases 1 and 2A. Toxicology 134:109-115. (Pubitemid 29248884)
117. Silverstein AM, Barrow CA, Davis AJ, and Mumby MC (2002) Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci U S A 99:4221-4226. (Pubitemid 34285967)
118. Skinner J, Sinclair C, Romeo C, Armstrong D, Charbonneau H, and Rossie S (1997) Purification of a fatty acid-stimulated protein-serine/threonine phosphatase from bovine brain and its identification as a homolog of protein phosphatase 5. J Biol Chem 272:22464-22471. (Pubitemid 27386055)
119. Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, and Mumby M (1993) The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 75:887-897. (Pubitemid 24014546)
120. Steegmaier M, Hoffmann M, Baum A, Léná rt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, et al. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-322.
121. Strack S, Zaucha JA, Ebner FF, Colbran RJ, and Wadzinski BE (1998) Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits. J Comp Neurol 392:515-527. (Pubitemid 28152405)
122. Strebhardt K and Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321-330.
123. Sun SC, Maggirwar SB, and Harhaj E (1995) Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites. J Biol Chem 270:18347-18351.
124. Swingle M, Ni L, and Honkanen RE (2007) Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 365:23-38.
125. Swingle MR, Honkanen RE, and Ciszak EM (2004) Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. J Biol Chem 279:33992-33999. (Pubitemid 39063050)
126. Tamura S, Toriumi S, Saito J, Awano K, Kudo TA, and Kobayashi T (2006) PP2C family members play key roles in regulation of cell survival and apoptosis. Cancer Sci 97:563-567. (Pubitemid 44056602)
127. Tappan E and Chamberlin AR (2008) Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site. Chem Biol 15:167-174.
128. Terrak M, Kerff F, Langsetmo K, Tao T, and Dominguez R (2004) Structural basis of protein phosphatase 1 regulation. Nature 429:780-784. (Pubitemid 38833131)
129. Tian Q and Wang J (2002) Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals 11:262-269. (Pubitemid 37494393)
130. Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7:833-846. (Pubitemid 44627477)
131. Trockenbacher A, Suckow V, Foerster J, Winter J, Krauss S, Ropers HH, Schneider R, and Schweiger S (2001) MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nat Genet 29:287-294. (Pubitemid 33096453)
132. Ugi S, Imamura T, Ricketts W, and Olefsky JM (2002) Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling. Mol Cell Biol 22:2375-2387. (Pubitemid 34224640)
133. Urban G, Golden T, Aragon IV, Cowsert L, Cooper SR, Dean NM, and Honkanen RE (2003) Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem 278:9747-9753. (Pubitemid 36800473)
134. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848. (Pubitemid 38174664)
135. von Kriegsheim A, Pitt A, Grindlay GJ, Kolch W, and Dhillon AS (2006) Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nat Cell Biol 8:1011-1016. (Pubitemid 44314733)
136. Wada T, Miyata T, Inagi R, Nangaku M, Wagatsuma M, Suzuki D, Wadzinski BE, Okubo K, and Kurokawa K (2001) Cloning and characterization of a novel subunit of protein serine/threonine phosphatase 4 from mesangial cells. J Am Soc Nephrol 12:2601-2608. (Pubitemid 33115406)
137. Walsh AH, Cheng A, and Honkanen RE (1997) Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 416:230-234. (Pubitemid 27475370)
138. Wang GS (1989) Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 26:147-162. (Pubitemid 19257209)
139. Wechsler T, Chen BP, Harper R, Morotomi-Yano K, Huang BC, Meek K, Cleaver JE, Chen DJ, and Wabl M (2004) DNA-PKcs function regulated specifically by protein phosphatase 5. Proc Natl Acad Sci U S A 101:1247-1252. (Pubitemid 38182674)
140. Westermarck J and Hahn WC (2008) Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 14:152-160.
141. Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson CW, and Appella E (2006) Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry 45:13193-13202. (Pubitemid 44707680)
142. Yamaguchi Y, Katoh H, Mori K, and Negishi M (2002) Galpha(12) and Galpha(13) interact with Ser/Thr protein phosphatase type 5 and stimulate its phosphatase activity. Curr Biol 12:1353-1358. (Pubitemid 34869889)
143. Yamashiro S, Yamakita Y, Totsukawa G, Goto H, Kaibuchi K, Ito M, Hartshorne DJ, and Matsumura F (2008) Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1. Dev Cell 14:787-797.
144. Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, Nairn AC, and Greengard P (1999) Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 2:13-17. (Pubitemid 30488934)
145. Yang J, Fan GH, Wadzinski BE, Sakurai H, and Richmond A (2001) Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem 276:47828-47833. (Pubitemid 37370677)
146. Yang J, Roe SM, Cliff MJ, Williams MA, Ladbury JE, Cohen PT, and Barford D (2005) Molecular basis for TPR domain-mediated regulation of protein phosphatase 5. EMBO J 24:1-10. (Pubitemid 40188458)
147. Yang SI, Lickteig RL, Estes R, Rundell K, Walter G, and Mumby MC (1991)
148. Yeo M, Lee SK, Lee B, Ruiz EC, Pfaff SL, and Gill GN (2005) Small CTD phosphatases function in silencing neuronal gene expression. Science 307:596-600. (Pubitemid 40165685)
149. Yeo M, Lin PS, Dahmus ME, and Gill GN (2003) A novel RNA polymerase II C-terminal domain phosphatase that preferentially dephosphorylates serine 5. J Biol Chem 278:26078-26085. (Pubitemid 36835376)
150. Yoda A, Xu XZ, Onishi N, Toyoshima K, Fujimoto H, Kato N, Oishi I, Kondo T, and Minami Y (2006) Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J Biol Chem 281:24847-24862. (Pubitemid 44274257)
151. Yuan H, Veldman T, Rundell K, and Schlegel R (2002) Simian virus 40 small tumor antigen activates AKT and telomerase and induces anchorage-independent growth of human epithelial cells. J Virol 76:10685-10691. (Pubitemid 35176184)
152. Zhang J, Bao S, Furumai R, Kucera KS, Ali A, Dean NM, and Wang XF (2005) Protein phosphatase 5 is required for ATR-mediated checkpoint activation. Mol Cell Biol 25:9910-9919. (Pubitemid 41572739)
153. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM, and Hahn WC (2003) Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3:483-495. (Pubitemid 38340295)
154. Zhou G, Golden T, Aragon IV, and Honkanen RE (2004) Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. J Biol Chem 279:46595-46605. (Pubitemid 39518304)